Advances in Subclinical and Clinical Trials and Immunosuppressive Therapies in Xenotransplantation
Xenotransplantation · 2025
DOI: 10.1111/xen.70053 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Xenotransplantation, 2025. Verfasst von Kai Xing und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medi…. Hauptthemen laut MEDLINE: Transplantation, Heterologous, Immunosuppressive Agents, Immunosuppression Therapy, Heterografts. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 232 Literaturangaben. Gefördert von: National Natural Science Fund for Distinguished Young Scholars of China, Frontier Biotechnology Key Project of National Key R & D Program of the Ministry of Science and Technology of China, Special Project of the Ministry of Science and Technology of China Supported by the State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Aca….
Abstract (Originalsprache)
Organ transplantation remains the foremost effective intervention for end‐stage organ failure. Nevertheless, the scarcity of donors has resulted in prolonged waiting times for countless patients globally. The advent of xenografts presents a promising solution to the organ shortage crisis. Although the utilization of xenografts has a long history, it is only in recent years that breakthroughs in genetically modified pigs have rendered successful xenotransplantation a feasible option. In the past 4 years, numerous subclinical and clinical trials have involved xenotransplantation from genetically modified pigs to humans. However, the outcomes have been disappointing, necessitating a reassessment of basic and preclinical research to address the emerging challenges. Furthermore, immunosuppressive therapies remain essential in xenotransplantation. The range of immunosuppressive agents, encompassing traditional immunosuppressants and monoclonal antibodies such as anti‐CD154/CD40 monoclonal antibodies, exhibits considerable diversity. However, the most effective drug combination for achieving optimal efficacy remains elusive. This review will offer a succinct overview of the results from recent clinical and subclinical xenotransplantation trials. Moreover, it will highlight recent advancements in immunosuppressive strategies and discuss potential future research directions in this field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Beijing Key Laboratory of Preclinical Research and Evaluation for Cardiovascular Implant Materials, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medic…
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Cardiac Surgery, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, China.
- Shenzhen Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, China.
Förderung
- National Natural Science Fund for Distinguished Young Scholars of China
- Frontier Biotechnology Key Project of National Key R & D Program of the Ministry of Science and Technology of China
- Special Project of the Ministry of Science and Technology of China Supported by the State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Aca…
- National Natural Science Foundation of China
Zitieren
APA
Xing, K., Chang, Y., Jia, H., & Song, J. (2025). Advances in Subclinical and Clinical Trials and Immunosuppressive Therapies in Xenotransplantation. Xenotransplantation. https://doi.org/10.1111/xen.70053
Vancouver
Xing K, Chang Y, Jia H, Song J. Advances in Subclinical and Clinical Trials and Immunosuppressive Therapies in Xenotransplantation. Xenotransplantation. 2025. doi:10.1111/xen.70053
BibTeX
@article{Xing2025,
author = {Xing, Kai and Chang, Yuan and Jia, Hao and Song, Jiangping},
title = {Advances in Subclinical and Clinical Trials and Immunosuppressive Therapies in Xenotransplantation},
journal = {Xenotransplantation},
year = {2025},
doi = {10.1111/xen.70053}
}
EUVIMED